BioCatalystWatch
KODWorkspace / KOD / OverviewCompany library
Price
Market cap
Next catalystPEAK Pivotal Analysis 1 topline data expected December 2026KSI-101 — MESI; PEAK and PINNACLE · Phase 3 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

VEGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

VEGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

KSI-101

VEGF × IL-6

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

KSI-101

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KSI-101

VEGF × IL-6

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

VEGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

VEGF

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

tarcocimab

VEGF

PreINDP1P2P3FilingApproved
KSI-101

VEGF × IL-6

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KOD PR & News

PR & News

KOD SEC archive